The Boros Group develops metal-based molecular imaging probes and therapeutics for personalized medicine. The group’s research focus includes early transition radiometal chemistry which has the potential to increase the availability of high-energy, biomedical cyclotrons to provide access to radiometals with properties suitable for PET imaging and radiotherapy; lanthanide-based imaging probes that combine radioactive and luminescent reporters in targeted molecular probes with the potential of providing real-time luminescence-guided surgery; and treatment of bacterial infections by using naturally occurring and synthetic siderophores to act as Trojan horses to deliver antibiotics to the site of infection.